This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Stereotactic Body Radiation Therapy (SBRT) for Liver Mets

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Dwight Heron, University of Pittsburgh
Information provided by (Responsible Party):
Dwight Heron, University of Pittsburgh Identifier:
First received: May 24, 2011
Last updated: April 24, 2017
Last verified: April 2017

This is a phase I dose escalation study. Dose escalation will be via the traditional "up and down" scheme. SBRT:

Patients will receive one of the following radiation regimens:

  • 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.
  • 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.
  • 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.

Condition Intervention Phase
Liver Metastases Radiation: Stereotactic Body Radiation Therapy Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases

Further study details as provided by Dwight Heron, University of Pittsburgh:

Primary Outcome Measures:
  • Maximum tolerated dose (MTD) and safety of SBRT for liver metastases using dose escalation [ Time Frame: 16 Months ]

    Dose limiting toxicity (DLT) will be defined as any grade III stomach, bowel, liver, or spinal cord toxicity, or any grade IV toxicity as defined by the RTOG. Only toxicities observed prior to 7 months after the last fraction of radiation will affect dose escalation.

    After escalation has stopped, de-escalation will begin at one dose level below the maximum achieved during escalation. If 3 pts have been treated, 3 pts are added; if 6 pts have been treated, this level will be declared the MTD, the highest dose level at which no more than 1 of 6 treated pt experiences a DLT.

Secondary Outcome Measures:
  • Local control associated with this local regional therapy [ Time Frame: 16 months ]
    Local control will be defined as stable disease, partial response, or complete response in the target lesion(s). Local failure will be defined as any progression of disease within the target volume. Regional failure will be defined as development of new liver metastases outside of the treated lesions. Distant failure will be defined as development of new metastatic lesions outside of the liver (brain, bone, etc).

  • Local response based on FDG-PET/CT compared to CT alone. [ Time Frame: 16 months ]
    Ideally, all follow-up FDG-PET/CT scans after chemo will be performed on the same scanner to help limit variability in the SUVs detected by different scanners. For those patients with non-FDG avid tumors, their response to therapy will be assessed by CT scan. The most recent consensus recommendations by the NCI on assessing PET response indicate semi-quantitative SUV (standard uptake value) analysis based on lean body mass and/or body surface area be used in determining 18F-FDG uptake. We will use the EORTC 1999 criteria for defining 18F-FDG response

  • Health Related Quality of Life (HRQL) associated with this SBRT [ Time Frame: 16 months ]
    Health related quality of life will be assessed using the Functional Assessment of Cancer Therapy-Hepatobiliary [FACT-Hep; Appendix V]. The FACT-Hep is part of the Functional Assessment of Chronic Illness Therapy (FACIT; 13) measurement system and includes the FACT-General (FACT-G) and an 18-item module specifically designed for patients diagnosed with hepatobiliary carcinomas.

Estimated Enrollment: 18
Study Start Date: September 2011
Estimated Study Completion Date: June 2020
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
SBRT Radiation: Stereotactic Body Radiation Therapy


Patients will receive one of the following radiation regimens:

  • 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.
  • 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.
  • 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.
Other Names:
  • CyberKnife
  • Trilogy
  • True Beam
  • Radiosurgery

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients ≥ 18 years of age
  • A life expectancy of at least 6 months with a Karnofsky performance status of at least 70
  • The target lesion(s) can be accurately measured in at least one dimension according to RECIST and must have a maximum tumor volume of ≤ 100 cm3
  • No prior radiotherapy to the upper abdomen
  • Previous systemic chemotherapy or non-radiation local therapy (such as surgery, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) is allowed. The lesion must however have shown criteria of progression based on RECIST. Local therapy must be completed at least 4 weeks prior to the baseline scan. This is to create a safer treatment environment and to help determine the effect of treatment by SBRT alone. Patients will be allowed to go onto appropriate systemic therapy, as determined by their medical oncologist, 2 weeks following delivery of SBRT
  • Patients with resectable disease will be eligible for participation if they have comorbidities precluding surgery or refuse to undergo an operation
  • Cirrhotic status of Child-Pugh class A or B
  • Patients can have extra-hepatic disease, provided the hepatic disease is the highest burden, the extra-hepatic disease is low burden and potentially treatable with surgery, ablative radiation therapy, or US Food and Drug Administration-approved first- or second-line systemic therapy regimens
  • Patient's will have no evidence of gross vascular invasion.
  • Patients will have no more than 3 distinct lesions, all being ≤ 3cm in greatest dimension, OR 1 lesion ≤ 6cm in greatest dimension
  • Platelet count ≥ 60 x 109/L, Hemoglobin ≥ 8.5 g/dL, WBC ≥ 2000/μL International normalized ratio (INR) must be ≤ 2.3. Patients who are being therapeutically anticoagulated with an agent such as Coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists
  • Other baseline labs must meet the following criteria: total bilirubin < 3mg/dl, albumin> 2.5mg/dl, and liver enzymes less than three times the upper limit of normal. Creatinine must also be < 1.8mg/dl or a creatinine clearance > 50ml/min
  • Must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomforts

Exclusion Criteria:

  • Renal failure requiring hemo- or peritoneal dialysis
  • Uncontrolled inter-current illness including, but not limited to ongoing or active infection (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 4.0), congestive heart failure (> New York Heart Association (NYHA) class 2), active coronary artery disease (CAD), cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), uncontrolled hypertension and any condition which could jeopardize the safety of the patient and his/her compliance in the study . Myocardial infarction more than 6 months prior to study entry is permitted
  • A history of variceal bleeding where the varices have not been eradicated or decompressed by shunt placement
  • History of an active connective tissue disorder
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  • Pregnant or breast-feeding patients are excluded from this study because abdominal radiation therapy has potential for teratogenic and/or abortifacient effects
  • Portal vein occlusion
  • Extensive liver tumor burden, defined as more than 75% of the liver.
  • Patients with primary tumor histology of lymphoma, leukemia, or germ cell tumor
  • Patients with hepatocellular carcinoma will be excluded from this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01360606

Contact: Dwight E Heron, MD 412-623-6720
Contact: Karen D Holeva 412-623-1275

United States, Pennsylvania
UPMC Cancer Centers Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Dwight E Heron, MD    412-623-6720   
Contact: Karen D Holeva    412-623-1275   
Sub-Investigator: Steven A Burton, MD         
Sub-Investigator: Allan Tsung, MD         
Sub-Investigator: David Gellar, MD         
Sub-Investigator: J. Wallace Marsh, MD         
Sub-Investigator: Melvin Deutsch, MD         
Sub-Investigator: John Flickinger, MD         
Sub-Investigator: Annette E Quinn, MSN         
Sub-Investigator: James M Mountz, MD         
Sub-Investigator: Jennifer Steel, PhD         
Sub-Investigator: Hong Wang, PhD         
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: Dwight E Heron, MD UPMC Shadyside
Principal Investigator: Rodney Wegner, MD UPMC Shadyside
  More Information

Responsible Party: Dwight Heron, Vice Chairman, University of Pittsburgh Identifier: NCT01360606     History of Changes
Other Study ID Numbers: 09-051
Study First Received: May 24, 2011
Last Updated: April 24, 2017

Keywords provided by Dwight Heron, University of Pittsburgh:

Additional relevant MeSH terms:
Neoplasm Metastasis
Liver Neoplasms
Neoplastic Processes
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases processed this record on August 23, 2017